Aims: Despite the therapeutic efficacy of statins and antiplatelet agents for atherosclerosis, monotherapy with each drug alone is often insufficient to achieve the patient's therapeutic goals. We previously showed that combined statin/antiplatelet agent/anti-tumor necrosis factor (TNF) agent therapy (pravastatin/sarpogrelate/ etanercept) reduces atherosclerotic lesions by inhibiting TNF, an atherogenic cytokine that contributes to the progression of arteriosclerosis. In addition, our previous study showed that combined treatment with pravastatin and cilostazol is effective for reducing TNF-driven inflammation through anti-TNF activity. Therefore, in the present study, we evaluated the additive effects of combined pravastatin and cilostazol therapy on atherosclerotic progression using low-density lipoprotein receptor (LDLR) knockout (KO) mice.
| INTRODUC TI ON
Atherosclerosis is well characterized as a chronic vascular inflammatory disease that involves hyperlipidemic processes as a consequence of the failure to regulate the inflammatory response within the vessel wall. Thus, the inflammatory response is implicated in the initiation and progression of atherosclerosis.
1,2 Tumor necrosis factor (TNF), which is one of the most important inflammatory cytokines, is known to contribute to the process of arteriosclerosis, for example, by affecting the lipid composition in the blood. 3 Given this pathological role of TNF, it is not surprising that anti-TNF therapy has become an important additional treatment strategy for atherosclerosis.
Anti-TNF therapy reduces the frequency of cardiac arrest and cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA). 4 In addition, long-term etanercept, adalimumab, and infliximab therapy improves aortic stiffness and carotid intima-media thickness (CIMT) progression in patients with inflammatory arthropathies.
5
TNF antagonists have been shown to have beneficial effects by preventing progression in atherosclerosis patients. 6 Moreover, it was recently found that the addition of the anti-TNF agent etanercept to the combination of pravastatin and sarpogrelate markedly improved the protective effect against atherosclerosis in elderly low-density lipoprotein receptor (LDLR) knockout (KO) mice.
7
Statins, a class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are cholesterol-lowering agents that are generally used as a conventional treatment for CVD. 8 In addition to their hypolipidemic activity, statins have immunomodulatory and anti-inflammatory properties that expand their clinical applications, including applications in the treatment of chronic and autoimmune disorders. 9, 10 Unlike other lipophilic statins, pravastatin is hydrophilic and excreted primarily in the kidneys and does not undergo metabolism via CYP450 to a significant extent. Therefore, pravastatin has minimum potential for drug-drug interactions in polypharmacy. 11 Antiplatelet agents have been widely reported to be effective in preventing the recurrence of cardiovascular events. 12 A number of studies have reported that antiplatelet agents act as anti-inflammatory drugs that inhibit the action of TNF and interleukin (IL)-8 during stroke pathogenesis and reduce the peripheral vascular disease-induced induction of plasma ICAM-1, VCAM-1, and TNF in patients. 13, 14 Among these antiplatelet agents, cilostazol, a potent inhibitor of phosphodiesterase, has been shown to have antiplatelet and vasodilatory effects and beneficial effects on the prevention of atherosclerosis. 15 Additionally, a previous study reported that cilostazol decreased IL-6, IL-1β, and TNF levels in myocardial ischemia/ reperfusion injury 16 and hypercholesterolemia-induced atherosclerosis models. 17 Previously, we reported that the combination of pravastatin and sarpogrelate is synergistically beneficial for atherosclerosis. In the pravastatin treatment group, decreases in serum TNF levels and atherosclerotic plaques were observed in LDLR KO mice. 18 Additionally,
another study reported that the antiatherogenic effect of cilostazol in LDLR KO mice included a reduced TNF-stained area in the aortic arches. 19 Moreover, our previous study showed that combined pravastatin and cilostazol treatment is effective for reducing TNF- investigated. In this study, we hypothesized that combined treatment with cilostazol and pravastatin might have a beneficial effect in reducing atherosclerotic disease progression. Therefore, the purpose of this study was to investigate the additive antiatherogenic efficacy of combined pravastatin and cilostazol treatment in an LDLR KO mouse model. 
| MATERIAL S AND ME THODS

| Experimental animals and diet
| Tissue and blood collection
Tissues and blood were prepared as previously described. 18 Briefly, blood was collected from the mice after 16 weeks of feeding. The
atherosclerosis, cilostazol, combination therapy, LDLR KO mice, pravastatin blood was retro-orbitally collected from each group of mice, and the serum was stored at −80°C and used for serum lipid analysis and cytokine determination (n = 5-6/group). The aorta and heart were perfused with PBS under anesthesia and collected for histochemical and immunohistochemical analyses. The thoracoabdominal aorta was fixed in 4% paraformaldehyde (Sigma) to measure arteriosclerotic plaque. The heart, including the aortic root, was harvested, washed, placed in paraformaldehyde for 24 hours at 4°C, embedded in embedding matrix (OCT Embedding Matrix, CellPath Ltd., Newtown, UK), and stored at −80°C for analysis.
| Oil Red O and immunohistochemical staining
The atherosclerotic burden of the thoracoabdominal aorta was 
| Serum lipid analysis and cytokine determination
Blood was retro-orbitally collected from each group of mice, and the serum was stored at −80°C and used for biochemical analysis (n = 5-6/ group were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.
| Statistical analysis
Data are expressed as the mean ± SEM. All statistical analyses were performed using Student's t test (GraphPad Prism software;
GraphPad, San Diego, CA, USA). Statistical significance was considered at P ≤ 0.05.
| RE SULTS
| Additive effect of combined pravastatin and cilostazol treatment on the reduction of aortic lipid deposition in LDLR KO mice
Although the combination of pravastatin and sarpogrelate 18 or the addition of etanercept 7 is effective for attenuating atherosclerosis in mice, our understanding of the activity of this treatment is incomplete in the context of the complex underlying pathogenesis of atherosclerosis. To examine whether the combination of pravastatin and cilostazol therapy could exert a beneficial protective effect against atherosclerotic progression, mice were orally administered pravastatin (40 mg/kg) and/or cilostazol (40 mg/kg) six times per week for 16 weeks, and the descending aortas were collected. Arterial lipid accumulation was detected by ORO staining of a cryosection of the aortic root. 20 As shown in Figure 1A ,B, the ORO-stained atherosclerotic plaque areas in the en face aortic preparations were significantly reduced after treatment with pravastatin or cilostazol alone compared to those from mice fed the HFD (*P < 0.05 and **P < 0.01, respectively). The protective effect of the combined pravastatin and cilostazol treatment was markedly better than that of either treatment alone (***P < 0.005). Similarly, the atherosclerotic plaque regions of the aortic roots in the combined pravastatin and cilostazol group showed significantly decreased lipid deposits in plaques compared to those in the HFD groups and in the groups that received either treatment alone ( Figure 1C ,D, ***P < 0.005). These findings demonstrate that combined pravastatin and cilostazol treatment exerts beneficial protective effects against atherosclerotic progression in LDLR KO mice. were significantly reduced in the pravastatin-and cilostazoltreated groups compared to those of the HFD group (*P < 0.05 and **P < 0.01, respectively). The effect of the combined pravastatin and cilostazol treatment was markedly better than that of either treatment alone (***P < 0.005).
As the serum cytokine levels of TNF and IL-6 are considered to be circulating biomarkers for atherosclerotic disease progression, we used ELISA to further assess whether combined treatment with pravastatin and cilostazol can provide an additive benefit for the serum levels of TNF and IL-6 in LDLR KO mice. As shown in Figure 3 , significantly lower serum levels of TNF and IL-6 were detected in the pravastatin-cilostazol combination therapy group than in the HFD group. Although pravastatin alone did not significantly downregulate cytokine levels, combined pravastatin and cilostazol treatment exerted an additive effect in reducing TNF and IL-6 serum levels (*P < 0.05, **P < 0.01, respectively). Taken
together, these results demonstrate that combined pravastatin F I G U R E 1 Combination therapy with pravastatin and cilostazol attenuates the atherosclerotic lesion area in the aortic artery in lowdensity lipoprotein receptor (LDLR) knockout (KO) mice. Ten-week-old male LDLR KO mice were fed a NFD (a) or a HFD (b) for 16 wk and treated with pravastatin (40 mg/kg orally six times weekly) (c), cilostazol (40 mg/kg orally six times weekly) (d), or a combination of pravastatin and cilostazol (40 mg/kg each orally six times weekly) (e) for 16 wk. Representative Oil Red O (ORO)-stained en face aortic preparation (A). Quantification of ORO-stained plaque areas (B). Representative images and quantification data of aortic root sections stained with ORO for each mouse group are shown (C,D). Error bars represent the standard error, and significance was analyzed by Student's t test (*P < 0.05, **P < 0.01, and ***P < 0.005, compared with HFD, n = 5-6/group). NFD, normal fat diet; HFD, high-fat diet; Pra, pravastatin; Cilo, cilostazol; MPK, mg/kg body weight
and cilostazol treatment can provide beneficial effects on the reduction in cellular risk factors and serum cytokine levels.
| Beneficial effect of combined pravastatin and cilostazol treatment on mean body weight and plasma lipid levels in LDLR KO mice
To further verify the beneficial effect of combined pravastatin and cilostazol treatment on atherosclerotic risk factors, after the mice were fed a NFD, a HFD, or a HFD with drugs for 16 weeks, the body weight and plasma lipids of each group of mice were measured. All mice gained weight progressively during the study (16 weeks) . The weight gain after 16 weeks of the HFD was almost completely normalized by the combined pravastatin and cilostazol treatment (Table 1) . After 16 weeks of HFD feeding, serum lipid levels were analyzed. Serum levels of TC (pravastatin: −21%, cilostazol: −5%) and TGs (pravastatin: −29%, cilostazol: −26%)
were significantly decreased in the pravastatin and cilostazol alone groups compared with those of the HFD group (Table 1B) .
Notably, in the pravastatin and cilostazol combined group, serum levels of TC (−38%), TGs (−49%) and LDL cholesterol (−26%) significantly decreased, whereas serum levels of HDL cholesterol (13%) increased relative to those of the HFD group. Taken to-
gether, these results demonstrate that combined pravastatin and F I G U R E 3 Significant suppression of tumor necrosis factor (TNF) production by pravastatin-cilostazol combination therapy. Inflammatory cytokines were analyzed with enzyme-linked immunosorbent assay kits. Briefly, blood was retro-orbitally collected before surgery to harvest the aorta. Serum was isolated, and TNF (A) and interleukin (IL)-6 (B) were measured. Error bars represent the standard error, and significance was analyzed by Student's t test (*P < 0.05 and **P < 0.01, compared with HFD, n = 5-6/group). Cilo, cilostazol; HFD, high-fat diet; MPK, mg/kg body weight; NFD, normal fat diet; Pra, pravastatin cilostazol therapy exerts beneficial protection against atherosclerotic progression.
| D ISCUSS I ON
Despite the therapeutic efficacy of statin and antiplatelet agents in patients with atherosclerosis, monotherapy with each drug alone is often insufficient to achieve therapeutic goals in patients.
21,22
Several studies suggested a new strategy that involves the combination of statins and antiplatelet agents due to their beneficial therapeutic effects. 23 Moreover, anti-inflammatory therapy for atherosclerosis is also an effective strategy based on the observation of immune activation and inflammation in atherosclerotic lesions. 24 Previously, we reported that TNF inhibition therapy would be useful in addition to existing therapies as a new strategy for the treatment of atherosclerosis patients. 7 In addition, our previous study showed that combined pravastatin and cilostazol treatment is effective for The results of this study showed that atherosclerotic plaque formation was reduced in en face ORO staining of the aortas and crosssectional aortic roots from mice in the combined treatment group compared to that in samples from mice in the HFD group (Figure 1 ).
Consistent with our results, recent studies have shown that patients receiving pravastatin have a reduced thickness of the carotid intimamedia and decreased plaque scores and that pravastatin improves plaque formation by reducing lipid deposits and alleviating plaque inflammatory responses in mice. 32, 33 Additionally, previous reports have shown that cilostazol has a beneficial effect on the progression of CIMT in patients. 15 Therefore, combined pravastatin and cilostazol treatment may be a more effective strategy for treating Cilo, cilostazol; HFD, high-fat diet; MPK, mg/kg body weight; NFD, normal fat diet; Pra, pravastatin. *P < 0.05, **P < 0.01, and ***P < 0.005, compared with the HFD group, n = 5-6/group.
atherosclerotic disease progression than treatment with either agent alone.
The endothelial expression of adhesion molecules and the infiltration of immune cells induced by TNF stimulation have been implicated in the initiation of atherosclerotic progression. 1, 34 In our study, the ICAM-1-and MOMA-2-stained areas of the cross-sectional aortic roots in the combination treatment group were significantly decreased than those in the groups treated with either pravastatin or cilostazol alone (Figure 2 ), suggesting that combination treatment improved the pro-inflammatory state in the vascular endothelium of LDLR mice due to decreased recruitment of immune cells. Recruited macrophages constitute the fatty streak and contribute to increased lesion size and the systemic production of inflammatory cytokines.
35
Lower expression of TNF and IL-6 was observed in the combination treatment group than in the groups treated with either pravastatin or cilostazol alone ( Figure 3) , coinciding with decreased macrophage populations and smaller plaque sizes in the aortas of LDLR mice (Figures 1 and 2 ).
Weight gain was observed after 16 weeks of the HFD, whereas weight loss was observed in the mice in the combined treatment group. This finding might be due to decreased cholesterol, which is linked to the overall reduction in TC, TGs, and LDL levels caused by combination therapy with pravastatin and cilostazol (Table 1A ).
In addition, weight loss, decreased levels of TC, TGs, and LDL, and increased levels of HDL were found in the mice in the combined treatment group relative to the mice in the HFD group (Table 1B) .
Cilostazol is known to increase HDL, and pravastatin also increases HDL in addition to lowering LDL in patients. 36, 37 Taken together, these results demonstrate that combination therapy with pravastatin and cilostazol could enhance the antiatherosclerotic effect of monotherapy with each drug, resulting in the modulation of serum cholesterol levels in LDLR mice.
In conclusion, our present results suggest that combination therapy with pravastatin and cilostazol exerts beneficial effects by decreasing atherosclerotic lesion progression and improving the proinflammatory state in the vascular endothelium through reduced adhesion molecule expression, immune cell infiltration, and cytokine levels. In addition, we showed that the combined pravastatin and cilostazol therapy induced the antiatherosclerotic modulation of serum cholesterol levels. Therefore, we conclude that combined treatment with pravastatin and cilostazol may be considered a more effective antiatherosclerotic strategy than treatment with either agent alone. 
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